Outlook Therapeutics, Inc. (OTLK)

Market Cap	124.90M
Revenue (ttm)	n/a
Net Income (ttm)	-94.05M
Shares Out	23.66M
EPS (ttm)	-5.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137,605
Open	5.20
Previous Close	5.23
Day's Range	5.17 - 5.44
52-Week Range	4.61 - 12.85
Beta	0.63
Analysts	Strong Buy
Price Target	48.20 (+812.88%)
Earnings Date	Dec 20, 2024

About OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The compa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 13, 2016
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: OTLK
• Website: https://www.outlooktherapeutics.com

Analyst Forecast

According to 7 analysts, the average rating for OTLK stock is "Strong Buy." The 12-month stock price forecast is $48.2, which is an increase of 812.88% from the latest price.

Price Target

$48.2

(812.88% upside)

Analyst Consensus: Strong Buy